| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Phibro Animal Health Corporation
$35.44
+0.79 (+2.28%)
0Pipeline Score NOT_PHARMA · Pre-Clinical
Market Cap
746.67 M
EPS
2.34
P/E Ratio
15.15 $
Value Trade
5.71 M
4.05 %
Week
4.67 %
1 Month
5.92 %
3 Month
-31.65 %
6 Month
14.49 %
5 Year
101.58 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
163.10 K
52 Week Range
28.25 - 60.08
% held by Insiders
48.66 %
% held by Institutions
52.7 %
Enterprise Value
1.31 B
Total Shares
21.06 M
Short %
5.73 %
Float Shares
20.91 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Phibro Animal Health Corporation
106Total events
1Upcoming
19Tier-1 (high impact)
2005 – 2026Coverage
Upcoming catalysts 1
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
Event history 2
TBD
◆Management ChangeCorporate
Subscribe to view catalyst details
TBD
▲Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 2%
Micro Cap (rank 913 of 931)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PAHC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PAHC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PAHC▲ +2.3%today
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
Phibro Animal Health Corporation will announce its fourth quarter and fiscal year 2026 financial results on August 26, 2026. A conference call and webcast will follow on August 27, 2026, at 9:00 AM Eastern Time. Interested parties can access the call and presentation slides via the company's investor website.
Read more →PAHCPhibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
Phibro Animal Health Corporation is set to participate in the Stifel Jaws & Paws Conference. The event will provide a platform for the company to engage with investors and discuss its strategies and outlook. Further details about the conference and the company's participation were not disclosed in the article.
Read more →PAHC▼ -26.2%on this news· ran to -37% by day 3
Phibro Animal Health Corporation to Participate in Bank of America Securities Health Care Conference
Phibro Animal Health Corporation is set to participate in the upcoming Bank of America Securities Health Care Conference. This event will provide an opportunity for the company to engage with investors and discuss its strategies and performance. Details regarding the date and format of the conference have not been specified.
Read more →PAHCPhibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Phibro Animal Health Corporation has reported its third-quarter results and provided updates on its financial guidance. The report includes key financial metrics and insights into the company's performance during the quarter. However, specific details regarding revenue or profit changes were not disclosed in the article.
Read more →PAHCPhibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance TEANECK, N.J.
Phibro Animal Health Corporation reported a strong financial performance for Q3 2026, with net sales increasing 10% and adjusted net income rising 19%. The results were bolstered by a robust Animal Health business, marked by a significant 13% sales increase. However, the Performance Products segment faced challenges, showing a 17% decrease in sales. The company also announced the establishment of a Sustainable Solutions Platform while navigating complexities related to regulatory developments and rising expenses.
Read more →PAHCPhibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership
Phibro Animal Health Corporation has launched a sustainable solutions platform named VERRATAIN™. This initiative is a result of a strategic partnership with VAXA Technologies, aimed at promoting verified sustainability solutions across the company. The details of the platform and its expected impact on the market were not elaborated in the article.
Read more →PAHCPhibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation has declared its quarterly dividend. The announcement reflects the company's ongoing commitment to returning value to its shareholders. Further details regarding the dividend amount and payment schedule were not provided in the article.
Read more →PAHCPhibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
Phibro Animal Health Corporation will announce its third quarter financial results on May 6, 2026. A conference call and webcast are scheduled for May 7, 2026, at 9:00 AM ET, allowing interested parties to engage with the company's management. A replay of the webcast will be available shortly after the live event.
Read more →PAHCPhibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials TEANECK, N.J.
Phibro Animal Health Corporation announced that Brazil's Ministry of Agriculture and Livestock has implemented a new regulatory framework for antimicrobials, prohibiting the use of certain performance-enhancing feed additives. This change aligns Brazil's regulations with those in other global markets and requires veterinarians' prescriptions for the use of specific antimicrobials. Phibro is cooperating with regulatory bodies to facilitate the transition and expects limited fiscal impact in 2026. The company is also introducing PhibroVet, a digital platform to manage and streamline veterinary prescriptions.
Read more →PAHCPhibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials
Phibro Animal Health Corporation has announced a change in the regulatory framework for antimicrobials in Brazil. This development may impact the market dynamics for animal health products. Further details on the implications of this change have not been provided in the article.
Read more →PAHCPhibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance TEANECK, N.J.
Phibro Animal Health Corporation reported robust financial results for its second quarter ending December 31, 2025, showcasing a 21% increase in net sales to $373.9 million and a substantial rise in net income to $27.5 million. The adjusted earnings also saw a notable increase, indicating strong operational performance and effective management. The company has raised its fiscal year 2026 guidance, reflecting confidence in continued growth driven by an integrated MFA portfolio and sustained demand in their nutritional and vaccine products. Overall, the results depict a positive trajectory for Phibro amidst a challenging global environment.
Read more →PAHCPhibro Animal Health Corporation Announces Leadership Transition - Jack Bendheim to assume the role of Executive Chairman; Daniel Bendheim named Chief Executive Officer and President TEANECK, N.J.
Phibro Animal Health Corporation has announced a leadership transition where current CEO Jack Bendheim will become Executive Chairman and Daniel Bendheim will take over as CEO and President effective July 1, 2026. This change is seen as crucial for the company's ongoing growth and strategic direction. Jack Bendheim, who has been with the company since 1969 and has led it since 1988, expressed confidence in Dani's ability to lead as they continue to prioritize customer focus and innovation. The Board of Directors fully supports this transition.
Read more →PAHCPhibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance TEANECK, N.J.
Phibro Animal Health Corporation reported strong financial results for its first quarter ending September 30, 2025, with net sales rising 40% to $363.9 million and adjusted earnings per share doubling to $0.73. The growth was primarily driven by the Animal Health segment, which experienced a 55% increase in sales, buoyed by high demand for minerals, nutritional products, and vaccines. While the overall operational performance was strong, the Performance Products segment faced a decline in revenue. The company also updated its financial guidance, raising expectations for the fiscal year.
Read more →PAHCPhibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance TEANECK, N.J.
Phibro Animal Health Corporation has reported strong financial results for its fourth quarter and fiscal year ending June 30, 2025, with substantial year-on-year growth in net sales and adjusted EBITDA. Key highlights include a 39% increase in net sales for Q4 2025, driven by robust demand across its Animal Health portfolio. The company has provided optimistic guidance for fiscal year 2026, reflecting confidence in continued growth. Despite some challenges such as decreased gross margins and increased expenses, the overall performance indicates successful execution of its business strategies.
Read more →PAHCPhibro Animal Health Corporation Declares Quarterly Dividend TEANECK, N.J.
Phibro Animal Health Corporation has announced a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend is payable on September 24, 2025, to shareholders of record as of September 3, 2025. This declaration reflects the company's ongoing financial health and commitment to providing returns to its investors.
Read more →PAHCPhibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors TEANECK, NJ
Phibro Animal Health Corporation has appointed Joyce J. Lee as a Class II director, effective immediately. This appointment fills a vacancy on the board and increases its size to nine directors, with six being independent. Ms. Lee has a strong background in animal health and has held executive positions at notable companies, contributing to her strategic and operational expertise. The company's CEO expressed optimism about her ability to drive value and enhance board effectiveness.
Read more →PAHCPhibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products TEANECK, N.J.
Phibro Animal Health Corporation has successfully completed the acquisition of Zoetis' medicated feed additive portfolio and select water-soluble products. This acquisition enhances Phibro's capabilities in animal health by complementing its existing product lineup and expanding its reach into 80 countries. The new offerings are anticipated to boost profitability and be accretive to Phibro's earnings. Financial details will be shared during the Q1 earnings call on November 7.
Read more →PAHC▲ +31.8%on this news
Zoetis to Sell Medicated Feed Additive Portfolio to Phibro Animal Health PARSIPPANY, NJ and TEANECK, NJ
Zoetis Inc. has entered a definitive agreement to sell its medicated feed additive portfolio to Phibro Animal Health for $350 million. This transaction is expected to complete in the second half of 2024 and involves over 37 product lines generating $400 million in revenue. The collaboration aims to enhance Phibro's offerings and profitability while allowing Zoetis to concentrate on its core animal health initiatives. Over 300 Zoetis employees are set to transition to Phibro as part of the deal.
Read more →PAHC▼ -7.4%on this news
Phibro Animal Health Corporation Announces Chief Financial Officer Changes TEANECK, N.J.
Phibro Animal Health Corporation has announced the resignation of its Chief Financial Officer, Damian Finio, effective September 29, 2023. Richard G. Johnson, who previously held the CFO position until 2020, will act as the interim CFO starting September 30, 2023, to ensure a smooth transition. The company recognizes Finio's contributions while emphasizing Johnson's experience in guiding the organization during this period.
Read more →PAHCPhibro Animal Health Corporation Reports Third Quarter and Year-to-Date Results TEANECK, N.J.
Phibro Animal Health Corporation reported its third-quarter results for the period ending March 31, 2023, highlighting both sales growth and significant declines in net income. While net sales increased by 3% to $245.7 million and 5% year-to-date, net income fell sharply by 43% to $10 million. The company's Animal Health segment showed strong performance with a 10% increase in sales, boosted by new vaccine launches in Latin America. Conversely, the Mineral Nutrition segment experienced reduced demand, leading to overall challenges amidst rising costs and increased operating expenses.
Read more →PAHCPhibro Animal Health Corporation Reports Second Quarter Results TEANECK, N.J.
Phibro Animal Health Corporation announced its financial results for the second quarter ending December 31, 2022. The company experienced a 5% increase in net sales to $244.6 million, although net income plummeted by 59% to $7.2 million. Despite higher revenues, selling and administrative costs surged, largely due to environmental remediation expenses. Adjusted EBITDA grew slightly, highlighting a mix of operational strengths and challenges.
Read more →PAHCPhibro Animal Health Corporation Announces the Appointment of Alejandro Bernal to Its Board of Directors and Declares Quarterly Dividend TEANECK, NJ
Phibro Animal Health Corporation has appointed Alejandro Bernal as a new independent director on its Board of Directors, enhancing board independence with a total of six independent members. Bernal, previously CEO of PetDx and former President of Mars Veterinary Health International, brings extensive experience from the animal health industry. The company also announced a quarterly cash dividend of $0.12 per share, payable on March 22, 2023, demonstrating a commitment to return value to shareholders. This marks a significant step for Phibro in strengthening its leadership team.
Read more →PAHCPhibro Animal Health Corporation Reports First Quarter Results, Revised Guidance TEANECK, N.J.
Phibro Animal Health Corporation Reports First Quarter Results, Revised Guidance TEANECK, N.J., November 9, 2022 (Business Wire) - Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its first quarter ended September
Read more →PAHC▲ +5.6%on this news
Phibro Animal Health Corporation Reports Third Quarter Results, Provides Revised Financial Guidance TEANECK, N.J.
Phibro Animal Health Corporation Reports Third Quarter Results, Provides Revised Financial Guidance TEANECK, N.J., May 4, 2022 (Business Wire) - Phibro Animal Health Corporation (Nasdaq:PAHC) today announced financial results for its third quarter ended March 31, 2022. "Our f
Read more →PAHCPhibro Animal Health Corporation Reports Second Quarter Results, Provides Revised Financial Guidance TEANECK, N.J.
Phibro Animal Health Corporation Reports Second Quarter Results, Provides Revised Financial Guidance TEANECK, N.J., February 9, 2022 (Business Wire) - Phibro Animal Health Corporation (Nasdaq:PAHC) today announced financial results for its second quarter ended December 31, 202
Read more →PAHCPhibro Animal Health Corporation Welcomes FDA Hearing on Mecadox TEANECK, NJ
Phibro Animal Health Corporation Welcomes FDA TEANECK, NJ, January 12, 2022 (Business Wire) -- Phibro Animal Health Corporation (NASDAQ:PAHC): Today, the Food and Drug Administration (FDA) provided notice in the Federal Register of its intention to hold a public hearing regard
Read more →PAHCPhibro Animal Health Corporation Reports First Quarter Results TEANECK, N.J.
Phibro Animal Health Corporation Reports First N.J., November 2, 2021 (Business Wire) - Phibro Animal Health Corporation (Nasdaq:PAHC) today announced financial results for its first quarter ended September 30, 2021. "I was most encouraged by first quarter sales performance as
Read more →PAHCPhibro Animal Health Corporation Announces $550 million Debt Refinancing TEANECK, N.J.
Animal Health Corporation Announces $550 million Debt Refinancing TEANECK, N.J., April 22, 2021, (Business Wire) -- Phibro Animal Health Corporation (NASDAQ:PAHC) announced today that on April 22, 2021, the Company entered into an amended and restated credit agreement. Under t
Read more →PAHCPhibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Guidance for Its Fiscal First Quarter TEANECK, N.J.
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Guidance for Its Fiscal First Quarter N.J., August 26, 2020 (Business Wire) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its fourth quarter a
Read more →PAHCPhibro Animal Health Corporation Reiterates Safety of Mecadox TEANECK, NJ
Phibro Animal Health Corporation Reiterates TEANECK, NJ, July 17, 2020 (Business Wire) -- (NASDAQ:PAHC) Today, the Food and Drug Administration (FDA) provided notice of Federal Register publication of its intention to take a number of actions related to its ongoing review of t
Read more →PAHCPhibro Animal Health Corporation Reports Third Quarter Results TEANECK, N.J.
Phibro Animal Health Corporation Reports Third Quarter Results TEANECK, N.J., May 7, 2020 (Business Wire) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its third quarter ended March 31, 2020. Highlights for the March 2020 quarter
Read more →PAHCPhibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Presents Financial Guidance TEANECK, N.J.
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Presents Financial Guidance TEANECK, N.J., August 27, 2019 (Business Newswire) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its fourth quarter and fi
Read more →PAHCPhibro Animal Health Corporation Acquires Business of Osprey Biotechnics, Inc. TEANECK, N.J.
Phibro Animal Health Corporation Acquires Business of Osprey Biotechnics, Inc. TEANECK, N.J., August 1, 2019 (Business Wire) - Phibro Animal Health Corporation ("Phibro") (NASDAQ:PAHC) today announced it has acquired the business and assets of Osprey Biotechnics, Inc. ("Ospre
Read more →PAHCPhibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Presents Financial Guidance and Announces an Increased Dividend TEANECK, N.J.
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Presents Financial Guidance and Announces an Increased Dividend TEANECK, N.J., August 27, 2018 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial resu
Read more →PAHCPhibro Animal Health Corporation Reports Third Quarter TEANECK, N.J.
Phibro Animal Health Corporation Reports TEANECK, N.J., May 7, 2018 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its third quarter ended March Highlights for the March 2018 quarter (compared to the March 2017 quar
Read more →PAHCPhibro Animal Health Corporation Reports Second Quarter and Updated Annual Financial Guidance TEANECK, N.J.
Phibro Animal Health Corporation Reports Second Quarter and Updated Annual Financial Guidance TEANECK, N.J., Feb. 05, 2018 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its second quarter ended December 31, 2017.
Read more →PAHCPhibro Animal Health Corporation Reports First Quarter TEANECK, N.J.
Phibro Animal Health Corporation Reports TEANECK, N.J., November 6, 2017 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its first quarter ended September 30, 2017. Highlights for the September 2017 quarter (compare
Read more →PAHCPhibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year TEANECK, N.J.
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year TEANECK, N.J., August 30, 2017 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its fourth quarter and fiscal year ended June 30, 2017. Highligh
Read more →PAHCPhibro Animal Health Corporation Reports Second Quarter TEANECK, N.J.
Phibro Animal Health Corporation Reports TEANECK, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its second quarter ended December 31, 2016. Highlights for the December 2016 quarter (compared to
Read more →PAHCPhibro Animal Health Corporation Announces Gerald Carlson Retirement, Larry Miller Promotion TEANECK, N.J.
Phibro Animal Health Corporation Announces Gerald Carlson Retirement, Larry Miller Promotion TEANECK, N.J., May 31, 2016 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced that Gerald Carlson, Chief Operating Officer, will retire after 14 years
Read more →PAHCPhibro Animal Health Corporation
Phibro Animal Health Corporation Reports Third Quarter TEANECK, N.J., May 9, 2016 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its third quarter ended March "Our third quarter was a continuation of many of the tr
Read more →PAHCPhibro Animal Health Corporation Reiterates Safety of Mecadox TEANECK, N.J.
Phibro Animal Health Corporation Reiterates Safety of Mecadox TEANECK, N.J., April 8, 2016 (GLOBE NEWSWIRE) - (NASDAQ:PAHC) Today, the Food and Drug Administration (FDA) issued a press release stating its intention to take the initial steps in the process to rescind its approv
Read more →PAHCPhibro Animal Health Corporation Announces Closing of Acquisition
Phibro Animal Health Corporation Announces Closing of Acquisition of Business of MVP Laboratories, Inc. TEANECK, N.J., January 25, 2016 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation ("Phibro") (NASDAQ:PAHC) today announced it has completed its purchase of the assets of
Read more →PAHCPhibro Animal Health Corporation to Acquire Business of
Phibro Animal Health Corporation to Acquire Business of MVP Laboratories, Inc., an Animal Vaccine and Adjuvant Manufacturer and Marketer TEANECK, N.J., January 12, 2016 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation ("Phibro") (NASDAQ:PAHC) today announced an agreement to
Read more →PAHCPhibro Animal Health Corporation Announces Entry into Collaboration Agreement, License Agreement and Intellectual Property Acquisition Agreement TEANECK, NJ
Phibro Animal Health Corporation Announces Entry into Collaboration Agreement, License Agreement and Intellectual Property Acquisition Agreement TEANECK, NJ, January 22, 2015 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation ("Phibro") (NASDAQ:PAHC) today announced it has a
Read more →PAHCPhibro Animal Health Corporation Reports
Phibro Animal Health Corporation Reports TEANECK, N.J., November 11, 2014 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its first quarter ended September 30, 2014. It also updated guidance for its fiscal year ending
Read more →PAHCPhibro Animal Health Corporation Reports Fourth Quarter and Annual Results TEANECK, N.J.
Phibro Animal Health Corporation Reports Fourth Quarter and Annual Results TEANECK, N.J., September 16, 2014 (GLOBE NEWSWIRE) - Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its fourth quarter and fiscal year ended June 30, 2014. It
Read more →PAHCFor release: IMMEDIATELY For additional information contact: Richard G. Johnson, Chief Financial Officer, or Richard C. Rosenzweig, General Counsel - (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES COMPLETION O
-------------------------------------------------------------------------------- For release: IMMEDIATELY For additional information contact: Richard G. Johnson, Chief Financial Officer, or Richard C. Rosenzweig, General Counsel - (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATI
Read more →PAHCFOR RELEASE: IMMEDIATELY FOR ADDITIONAL INFORMATION CONTACT: RICHARD G. JOHNSON, CHIEF FINANCIAL OFFICER, OR RICHARD C. ROSENZWEIG, GENERAL COUNSEL -- (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION AND PAHC HOLDINGS COR
FOR RELEASE: IMMEDIATELY FOR ADDITIONAL INFORMATION CONTACT: RICHARD G. JOHNSON, CHIEF FINANCIAL OFFICER, OR RICHARD C. ROSENZWEIG, GENERAL COUNSEL -- (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION AND PAHC HOLDINGS CORPORATION ANNOUNCE RECEIPT OF REQUISITE CONSENTS AND SET
Read more →PAHCy22885aexv99w1.txt PRESS RELEASE For release: IMMEDIATELY For additional information contact: Richard G. Johnson, Chief Financial Officer, or Richard C. Rosenzweig, General Counsel - (201) 329-7300 PHIBRO ANIMAL HEALTH C
For release: IMMEDIATELY For additional information contact: Richard G. Johnson, Chief Financial Officer, or Richard C. Rosenzweig, General Counsel - (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION AND PAHC HOLDINGS CORPORATION ANNOUNCE COMMENCEMENT OF TENDER OFFERS FOR THRE
Read more →PAHCFOR RELEASE: IMMEDIATELY FOR ADDITIONAL INFORMATION CONTACT: RICHARD G. JOHNSON, CHIEF FINANCIAL OFFICER - (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES THE SALE OF WYCHEM LTD. RIDGEFIELD PARK, NEW JERSEY, AP
FOR RELEASE: IMMEDIATELY FOR ADDITIONAL INFORMATION CONTACT: RICHARD G. JOHNSON, CHIEF FINANCIAL OFFICER - (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES THE SALE OF WYCHEM LTD. RIDGEFIELD PARK, NEW JERSEY, APRIL 29, 2005 - Phibro Animal Health Corporation (the "C
Read more →PAHCFor additional information contact: Richard G. Johnson, Chief Financial Officer - 201 329-7300. Phibro Animal Health Corporation and Philipp Brothers Netherlands III BV extend expiration date
For additional information contact: Richard G. Johnson, Chief Financial Officer Phibro Animal Health Corporation and Philipp Brothers Netherlands III BV extend expiration date of exchange offer for units consisting of their 13% Senior Secured Notes due 2007 until 5:00 p.m., Ne
Read more →PAHCFor release: IMMEDIATELY For additional information contact: Richard G. Johnson, Chief Financial Officer (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES REDEMPTION OF SERIES C PREFERRED STOCK FROM PALLADIUM Rid
For release: IMMEDIATELY For additional information contact: Richard G. Johnson, Chief Financial Officer (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES REDEMPTION OF SERIES C PREFERRED STOCK FROM Ridgefield Park, New Jersey, February 28, 2005 Phibro Animal Health Co
Read more →PAHCy05870exv99w1.txt PRESS RELEASE FOR RELEASE: IMMEDIATELY FOR ADDITIONAL INFORMATION CONTACT: RICHARD G. JOHNSON, CHIEF FINANCIAL OFFICER - (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES FORMATION OF HOLDING CO
FOR RELEASE: IMMEDIATELY FOR ADDITIONAL INFORMATION CONTACT: RICHARD G. JOHNSON, CHIEF FINANCIAL OFFICER - (201) 329-7300 PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES FORMATION OF HOLDING COMPANY AND ISSUANCE BY HOLDING COMPANY OF NOTES TO FINANCE REDEMPTION OF SERIES C PREFER
Read more →PAHCFOR RELEASE: IMMEDIATELY FOR ADDITIONAL INFORMATION CONTACT: RICHARD G. JOHNSON, CHIEF FINANCIAL OFFICER, OR STEVEN L. COHEN, GENERAL COUNSEL - (201) 944-6020 PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES RECEIPT OF APPROVA
FOR RELEASE: IMMEDIATELY FOR ADDITIONAL INFORMATION CONTACT: RICHARD G. JOHNSON, CHIEF FINANCIAL OFFICER, OR STEVEN L. COHEN, GENERAL COUNSEL - (201) 944-6020 PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES RECEIPT OF APPROVAL TO AMEND INDENTURE FORT LEE, NEW JERSEY, DECEMBER 9,
Read more →PAHCCONSENT SOLICITATION STATEMENT PHIBRO ANIMAL HEALTH CORPORATION SOLICITATION OF CONSENTS RELATING TO 105,000 UNITS CONSISTING OF $85,000,000 13% SENIOR SECURED NOTES DUE 2007 OF PHIBRO ANIMAL HEALTH CORPORATION AND $20,0
CONSENT SOLICITATION STATEMENT CONSENT SOLICITATION STATEMENT PHIBRO ANIMAL HEALTH CORPORATION SOLICITATION OF CONSENTS 105,000 UNITS CONSISTING OF $85,000,000 13% SENIOR SECURED NOTES DUE 2007 OF PHIBRO ANIMAL HEALTH CORPORATION $20,000,000 13% SENIOR SECURED NOTES DUE 20
Read more →Competitive Position
How PAHC ranks across every disease it competes inCompetitive Position is a premium feature
See how PAHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial